anonymous
Guest
anonymous
Guest
Am I the only one who thinks this is an average opportunity at best? ONE drug with a limited market. A huge competitor in the horizon. A car allowance and a shitty one at that. Below average salary. Average benefits. I just don't get all of the desperation on here. I'd get it if this were a huge, market changing drug with great salaries and bonus potential. Neurocrine is not that.